CA2284001A1 - Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase - Google Patents

Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase Download PDF

Info

Publication number
CA2284001A1
CA2284001A1 CA002284001A CA2284001A CA2284001A1 CA 2284001 A1 CA2284001 A1 CA 2284001A1 CA 002284001 A CA002284001 A CA 002284001A CA 2284001 A CA2284001 A CA 2284001A CA 2284001 A1 CA2284001 A1 CA 2284001A1
Authority
CA
Canada
Prior art keywords
cells
pharmaceutically acceptable
deprenyl
administration
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284001A
Other languages
English (en)
Inventor
Keith Tipton
Carmel Mothersill
Robert Mooney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Enterprise Ireland
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284001A1 publication Critical patent/CA2284001A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation d'inhibiteurs de la monoamine-oxydase (MAO), dans la protection ou le sauvetage de cellules normales contre les effets secondaires toxiques provoqués par une irradiation ou l'administration d'agents chimiothérapeutiques tels que certains agents anti-cancéreux. Le déprényle est un inhibiteur de MAO particulièrement préféré.
CA002284001A 1997-03-13 1998-03-13 Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase Abandoned CA2284001A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IES970189 1997-03-13
IE970189 1997-03-13
PCT/IE1998/000023 WO1998040102A1 (fr) 1997-03-13 1998-03-13 Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase

Publications (1)

Publication Number Publication Date
CA2284001A1 true CA2284001A1 (fr) 1998-09-17

Family

ID=11041418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284001A Abandoned CA2284001A1 (fr) 1997-03-13 1998-03-13 Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase

Country Status (4)

Country Link
EP (1) EP0975366A1 (fr)
AU (1) AU6417198A (fr)
CA (1) CA2284001A1 (fr)
WO (1) WO1998040102A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1592301A (en) * 1999-11-11 2001-06-06 Fred Hutchinson Cancer Research Center Novel topoisomerase poisons for the treatment of proliferative disorders
US7173063B1 (en) 2000-11-10 2007-02-06 Fred Hutchinson Cancer Research Center Topoisomerase poisons for the treatment of proliferative disorders
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (fr) 2010-03-03 2016-05-11 Probiodrug AG Inhibiteurs de glutaminyl cyclase
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2776020B1 (fr) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Méthodes pour le traitement de tumeurs de la peau
CA2809364A1 (fr) * 2012-10-09 2014-04-09 Brandon University (-)-deprenyle et composes connexes pour le traitement de l'alopecie
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3931189A4 (fr) 2019-02-27 2022-11-30 The Regents Of The University Of California Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506204A (ja) * 1991-04-04 1994-07-14 ザ・ユニバーシティ・オブ・トロント・イノベイションズ・ファウンデイション 神経細胞機能を維持し、喪失を防止し、または回復させるためのデプレニールの使用
JP3258027B2 (ja) * 1996-03-15 2002-02-18 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレジリン投与による末梢ニューロパシーの予防および治療方法

Also Published As

Publication number Publication date
AU6417198A (en) 1998-09-29
EP0975366A1 (fr) 2000-02-02
WO1998040102A1 (fr) 1998-09-17

Similar Documents

Publication Publication Date Title
CA2284001A1 (fr) Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase
KR100720205B1 (ko) 종양 질환의 치료를 위한 약물의 조합(예를 들어,클로르프로마진과 펜타미딘)
Blumenkranz et al. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation
AU608824B2 (en) Agent for the prophylaxis and therapy of retroviral infections
JP4188416B2 (ja) 有意なホルモン活性のないチロキシン類縁体による悪性腫瘍の治療方法
US6245807B1 (en) Treatment of human prostate disease
EP3718560A2 (fr) Inhibiteurs de kinases dépendant de la cycline et leurs procédés d'utilisation
EP0196415A2 (fr) Trichostatines A et C comme agents anti-tumeurs
KR20010020611A (ko) 항산화제에 의한 과증식질병 치료의 향상
WO2006106915A1 (fr) AGENT PROTECTEUR POUR LA CELLULE NEURONALE RETINIENNE CONTENANT UN DERIVE DE PROSTAGLANDINE F2α COMME INGREDIENT ACTIF
TW200916101A (en) Telomerase activating compounds and methods of use thereof
USRE40155E1 (en) Methods for treatment of benign and malignant tumors, including lymphomas, leukemias, and leiomyomas
Fantini et al. Suramin inhibits proliferation of rat glioma cells and alters N‐cam cell surface expression
AU757541B2 (en) Use of adenosine agonists in cancer therapy
US20070071717A1 (en) Treatment of B cells with IL-21 and B cell activators induces Granzyme B production
Yoshida et al. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene.
Sandler et al. Decreased cell replication and polyamine content in insulin-producing cells after exposure to human interleukin 1β
EP2207548B1 (fr) Thérapie du cancer du sein
JP2007523190A (ja) 肺癌の治療のためのβ−ラパコンの使用
US6124326A (en) Use of flupirtine for the prophylaxis and therapy of disorders which are associated with an unphysiologically high cell death rate
EP1469858B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse utilises en tant qu'antagonistes de proliferation cellulaire et en tant qu'inducteurs de differenciation cellulaire
KR20030019371A (ko) 고수준의 글루타티온과 관련된 종양 치료에 있어서 치환된아크릴로일 디스타마이신 유도체의 용도
Ponzoni et al. Morphologic and phenotypic changes of human neuroblastoma cells in culture induced by cytosine arabinoside
Drewinko et al. Lethal activity and kinetic response of cultured human cells to 4′-(9-acridinylamino) methanesulfon-m-anisidine
WO1997011691A1 (fr) Traitement du cancer de la prostate chez l'homme

Legal Events

Date Code Title Description
FZDE Discontinued